{"component": "definition", "props": {"groups": [{"samples": [{"hash": "hanP4jIx209", "uri": "/contracts/hanP4jIx209#further-development", "label": "Occupation Right Agreement", "score": 35.1318730657, "published": true}, {"hash": "izTsK8Ij5vb", "uri": "/contracts/izTsK8Ij5vb#further-development", "label": "Occupation Right Agreement", "score": 27.7802874743, "published": true}, {"hash": "3lazI6B0wRe", "uri": "/contracts/3lazI6B0wRe#further-development", "label": "Occupation Right Agreement", "score": 27.2861054073, "published": true}], "snippet_links": [{"key": "the-facilities", "type": "clause", "offset": [50, 64]}, {"key": "rest-home", "type": "definition", "offset": [75, 84]}, {"key": "the-village", "type": "clause", "offset": [99, 110]}], "snippet": "means any improvement, extension or alteration to the facilities, Units or Rest Home Apartments in the Village.", "size": 8, "hash": "b841bde24b12b305747088b85c306f1e", "id": 1}, {"samples": [{"hash": "5LpG8x0QcCJ", "uri": "/contracts/5LpG8x0QcCJ#further-development", "label": "Occupation Right Agreement", "score": 33.562888348, "published": true}, {"hash": "cIpf2i8EWX2", "uri": "/contracts/cIpf2i8EWX2#further-development", "label": "Occupation Right Agreement", "score": 32.320013798, "published": true}, {"hash": "llRfXSMZ3XN", "uri": "/contracts/llRfXSMZ3XN#further-development", "label": "Occupation Right Agreement", "score": 30.7157748414, "published": true}], "snippet_links": [{"key": "development-defined", "type": "clause", "offset": [14, 33]}, {"key": "clause-15", "type": "clause", "offset": [37, 46]}, {"key": "occupation-right-agreement", "type": "definition", "offset": [55, 81]}], "snippet": "means further development defined in clause 15 of this Occupation Right Agreement.", "size": 5, "hash": "9f6b94a2848bffad4dc98d297e4bb83c", "id": 2}, {"samples": [{"hash": "k40FbwQNfsQ", "uri": "/contracts/k40FbwQNfsQ#further-development", "label": "Research and License Agreement (Chemgenex Pharmaceuticals LTD)", "score": 19.0, "published": true}, {"hash": "fzfOwIZ1ijO", "uri": "/contracts/fzfOwIZ1ijO#further-development", "label": "Research and License Agreement (Chemgenex Pharmaceuticals LTD)", "score": 19.0, "published": true}, {"hash": "2ml4qtJJnEp", "uri": "/contracts/2ml4qtJJnEp#further-development", "label": "Research and License Agreement (Chemgenex Pharmaceuticals LTD)", "score": 19.0, "published": true}], "snippet_links": [{"key": "the-program", "type": "clause", "offset": [6, 17]}, {"key": "research-and-development", "type": "definition", "offset": [29, 53]}, {"key": "in-relation-to", "type": "clause", "offset": [54, 68]}, {"key": "potential-product", "type": "definition", "offset": [82, 99]}, {"key": "completion-of", "type": "definition", "offset": [117, 130]}, {"key": "stage-2-research", "type": "definition", "offset": [131, 147]}], "snippet": "means the program of further research and development in relation to a Product or potential Product undertaken after completion of Stage 2 Research.", "size": 3, "hash": "06b02168d875b0fb282c5b965b0e825b", "id": 3}, {"samples": [{"hash": "aAfENB6JLSU", "uri": "https://www.sec.gov/Archives/edgar/data/73887/000119312513433241/d622799dex1069.htm", "label": "Bristow Group Inc", "score": 8.8494182067, "published": false}, {"hash": "kLZYd4xgqA3", "uri": "https://www.sec.gov/Archives/edgar/data/73887/000119312513231745/d538801dex1069.htm", "label": "Bristow Group Inc", "score": 8.3894592745, "published": false}, {"hash": "kfbiaLCMHk5", "uri": "http://ir.bristowgroup.com/static-files/654f05a0-7bca-4d8e-a4d6-6862390f6d49", "label": "ir.bristowgroup.com", "score": 8.1704312115, "published": false}], "snippet_links": [{"key": "further-work", "type": "clause", "offset": [6, 18]}, {"key": "schedule-5", "type": "definition", "offset": [50, 60]}, {"key": "ipr-ownership", "type": "clause", "offset": [62, 75]}], "snippet": "means further work as defined in paragraph 5.1 of Schedule 5 (IPR Ownership);", "size": 3, "hash": "69c6aef4772fedeb9ba83e479e4cc534", "id": 4}, {"samples": [{"hash": "aB0V6WrjGch", "uri": "/contracts/aB0V6WrjGch#further-development", "label": "Development and Supplemental Agreement to Amended and Restated License Agreement", "score": 31.340862423, "published": true}, {"hash": "5qZMSUk1DNh", "uri": "/contracts/5qZMSUk1DNh#further-development", "label": "Development and Supplemental Agreement to Amended and Restated License Agreement (Alkermes Plc.)", "score": 23.3894592745, "published": true}], "snippet_links": [{"key": "the-development-plan", "type": "clause", "offset": [6, 26]}, {"key": "development-product", "type": "clause", "offset": [35, 54]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [68, 92]}, {"key": "set-out", "type": "definition", "offset": [96, 103]}, {"key": "schedule-1", "type": "definition", "offset": [107, 117]}, {"key": "from-time-to-time", "type": "clause", "offset": [159, 176]}, {"key": "amendment-to-the", "type": "clause", "offset": [196, 212]}, {"key": "in-accordance-with", "type": "definition", "offset": [260, 278]}, {"key": "this-agreement", "type": "clause", "offset": [293, 307]}], "snippet": "means the development plan for the Development Product, Plan\u201d which as of the Effective Date is set out in Schedule 1, as it may be amended by Elan and Acorda from time to time and set out in any amendment to the Further Development Plan that may be generated in accordance with Clause 3.2 of this Agreement.", "size": 3, "hash": "02ecc06512278922105d8c8f6bd826f2", "id": 5}, {"samples": [{"hash": "eh1H4aw3xLR", "uri": "/contracts/eh1H4aw3xLR#further-development", "label": "Collaboration Agreement (Gene Logic Inc)", "score": 18.0, "published": true}, {"hash": "de0q7KFaRos", "uri": "/contracts/de0q7KFaRos#further-development", "label": "Collaboration Agreement (Gene Logic Inc)", "score": 18.0, "published": true}], "snippet_links": [], "snippet": "shall have the meaning set forth in Section 2.7.", "size": 3, "hash": "4dcc33c8c536e32000e26d5dd3da150d", "id": 6}, {"samples": [{"hash": "eh1H4aw3xLR", "uri": "/contracts/eh1H4aw3xLR#further-development", "label": "Collaboration Agreement (Gene Logic Inc)", "score": 18.0, "published": true}, {"hash": "de0q7KFaRos", "uri": "/contracts/de0q7KFaRos#further-development", "label": "Collaboration Agreement (Gene Logic Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "gene-target", "type": "definition", "offset": [5, 16]}, {"key": "therapeutic-product", "type": "definition", "offset": [26, 45]}, {"key": "protein-product", "type": "definition", "offset": [75, 90]}], "snippet": "of a Gene Target as (i) a Therapeutic Product will be the [***]; or (ii) a Protein Product will include the [***].", "size": 2, "hash": "46d53d82bc047967fb6d598a154a35f8", "id": 7}, {"samples": [{"hash": "dJzJYNiS6gf", "uri": "http://www.cityofenglewood.org/filestorage/9306/1441/1760/2267/1405/2104/3449/agenda_726111.pdf", "label": "www.cityofenglewood.org", "score": 3.7761806982, "published": false}], "snippet_links": [{"key": "final-site-plan-approval", "type": "clause", "offset": [48, 72]}, {"key": "after-june-1", "type": "clause", "offset": [73, 85]}], "snippet": "means development which receives preliminary or final site plan approval after June 1, 2011.", "size": 2, "hash": "acadb165dc1658ceb8daaafd217c8209", "id": 8}, {"samples": [{"hash": "9rQyZmflyPl", "uri": "/contracts/9rQyZmflyPl#further-development", "label": "Genomic Database Collaboration and License Agreement (Gene Logic Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "gene-target", "type": "definition", "offset": [5, 16]}, {"key": "therapeutic-product", "type": "definition", "offset": [26, 45]}, {"key": "protein-product", "type": "definition", "offset": [116, 131]}, {"key": "confidential-treatment-requested", "type": "definition", "offset": [215, 247]}], "snippet": "of a Gene Target as (i) a Therapeutic Product described in Section 1.35(a) will be the [ . . . *** . . .] or (ii) a Protein Product or a Therapeutic Product described in Section 1.35(b) will be [ . . . *** . . .]. *Confidential Treatment Requested", "size": 1, "hash": "46ab39731337b332c66a58e26791cc69", "id": 9}, {"samples": [{"hash": "jUaLgMwhKRY", "uri": "/contracts/jUaLgMwhKRY#further-development", "label": "Genomic Database Collaboration and License Agreement (Gene Logic Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "gene-target", "type": "definition", "offset": [5, 16]}, {"key": "therapeutic-product", "type": "definition", "offset": [26, 45]}, {"key": "commencement-of", "type": "clause", "offset": [90, 105]}, {"key": "development-of", "type": "clause", "offset": [169, 183]}, {"key": "protein-product", "type": "definition", "offset": [222, 237]}, {"key": "diagnostic-product", "type": "clause", "offset": [293, 311]}, {"key": "nucleic-acid", "type": "definition", "offset": [317, 329]}, {"key": "confidential-treatment-requested", "type": "definition", "offset": [331, 363]}], "snippet": "of a Gene Target as (i) a Therapeutic Product described in Section 1.40(a) shall mean the commencement of screening of a compound or compounds for the identification or development of such a Therapeutic Product; (ii) as a Protein Product, a Therapeutic Product described in Section 1.40(b), a Diagnostic Product or a Nucleic Acid *CONFIDENTIAL TREATMENT REQUESTED", "size": 1, "hash": "7b1fabd42d079f675295b186bc8e44f1", "id": 10}], "next_curs": "CmASWmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjwLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIcZnVydGhlci1kZXZlbG9wbWVudCMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"title": "Further Development", "snippet": "means any improvement, extension or alteration to the facilities, Units or Rest Home Apartments in the Village.", "size": 29, "id": "further-development", "examples": ["The Resident shall not be entitled to make any objection or claim compensation in respect of the <strong>Further Development</strong> and shall if required by the Operator sign all consents and other documents as may be required to give effect thereto.", "Article 10 (Committee) of the License Agreement shall be read as if it additionally referred to the <strong>Further Development</strong> Plan and its budget as appropriate.", "Within [***] (which period may be extended by mutual agreement of the Parties) following a <strong>Further Development</strong> Approval, the JSC will discuss in good faith and approve an initial Development Plan.", "In the event that Gr\u00fcnenthal shares in the cost of any such <strong>Further Development</strong> Study, [ * ].", "The Development Plan will include (a) all Development and Manufacturing activities to be performed following <strong>Further Development</strong> Approval, up to and including obtaining Regulatory Approval for Licensed Products in the Territory, (b) timelines for the performance of all activities set forth therein, and (c) a Development Budget for the conduct of activities set forth in such Development Plan.", "Should a Party desire to conduct <strong>Further Development</strong> Studies for the Licensed Product, the Parties shall discuss the possible conduct of such development activities, including any sharing of costs.", "Notwithstanding any provisions to the contrary set forth in this Agreement, the remaining terms of this Article 6 will not become effective until the date of <strong>Further Development</strong> Approval; provided that, prior to such <strong>Further Development</strong> Approval, the JSC may discuss and prepare an initial tentative Development Plan to help inform the JSC decision as to whether to provide a <strong>Further Development</strong> Approval.", "If the other Party provides notice to such notifying Party within [***] of receiving such Continuation Notice that it also desires to continue to progress the Program, then the <strong>Further Development</strong> Approval or Commercialization Approval, as applicable, will be deemed to be provided by the JSC on the date of such notice.", "Gr\u00fcnenthal shall be required to obtain AcelRx\u2019s consent before conducting such <strong>Further Development</strong> Studies for the Licensed Product, such consent not to be unreasonably withheld.", "Whilst Lipha is continuing Stage 1 Research, Stage 2 Research, <strong>Further Development</strong> or paying royalties to Autogen under any Commercialisation Licence, Lipha has a non-exclusive royalty free right to use the Pre-Stage 2 Results for the purposes of its own internal research for human therapeutic purposes."], "related": [["major-development", "Major development", "Major development"], ["infill-development", "Infill development", "Infill development"], ["experimental-development", "experimental development", "experimental development"], ["affordable-development", "Affordable development", "Affordable development"], ["cluster-development", "Cluster development", "Cluster development"]], "related_snippets": [], "updated": "2025-07-06T21:58:36+00:00"}, "json": true, "cursor": ""}}